Abstract
Liquid biopsy analyses of circulating tumor DNA are emerging as transformative tools for colorectal cancer management, enabling disease detection, monitoring, and treatment. Here, we critically assess its evidence-based utility in current clinical practice, seeking to align physicians’ and patients’ expectations.